TP53 and non-Hodgkin lymphoma: They found that significantly increased non-Hodgkin lymphomas risk was found in TP53 Arg72Pro polymorphism heterozygote model (Arg/Pro vs. Arg/Arg: OR = 1.18, 95% CI = 1.02–1.35) and dominant model (Arg/Pro+Pro/Pro vs. Arg/Arg: OR = 1.18, 95% CI = 1.03–1.34).